HAYA Therapeutics Announces Collaboration with Eli Lilly

5 September 2024

HAYA Therapeutics SA, a Swiss biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics, announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The partners will identify multiple regulatory genome derived RNA-based drug targets to address these chronic conditions.

Under the terms of the collaboration, HAYA will receive an upfront payment, including an equity investment, and is eligible to receive up to an aggregate USD 1 billion in pre-clinical, clinical and commercial milestone payments, as well as royalties on product sales.

VISCHER advised Haya Therapeutics SA on the Swiss legal aspects of the transaction. Cooley acted as lead counsel in this transaction. The VISCHER team included Christian Wyss (Partner, Corporate / M&A), Pauline Pfirter (Senior Associate, Corporate / M&A), Lukas Wendt (Associate, Corporate / M&A), Ariane Cottiati (Junior Associate Corporate / M&A) and Celine Kappler (Junior Associate, Corporate / M&A).

Authors: Christian Wyss, Pauline Pfirter, Lukas Wendt, Ariane Cottiati, Celine Kappler